Biovel Life Sciences has been founded with the primary focus of delivering quality health care products to people across the globe at affordable prices. Operating in the areas of vaccines, therapeutic molecules, wound management products and novel drug delivery systems, the company is committed to fostering biotechnology innovation and leveraging global technologies to deliver cost effective therapies in India and elsewhere. Biovel believes that it is well poised to cater to the needs of the global market with its qualified and dedicated scientists and experienced management team.

Biovel is striving for international collaborations with countries located in the US, Europe and Asia. It has concluded a collaborative agreement with Dow Pharma ( a strategic business unit of the $ 49 billion Dow Chemicals, Inc., USA) for the production of Human Growth Hormone (HGH), using Pfenix Expression Technology.

Biovel is open for business association with prospective partners to market its range of products in the international markets.

Biovel’s business model encompasses both Products and services.

The outline of Business Model is :

Business Avenues:

Biovel, with its distinct locational advantage is open for business associations with pharmaceutical and biotechnology companies located all around the globe. Our business model encourages and actively pursues:

Contract manufacturing Contract fill-finish operations (for vials and syringes) Contract formulation development Development of drug delivery systems, and Contract research

Sales & Marketing team:

Biovel has a very strong, aggressive and result-oriented marketing team spread across all the major and minor cities of India. The key members of the marketing team have decades worth of proven marketing experience behind them and are extensively exposed to pharma, biopharma and biotech markets.